Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermex Dermex II

Executive Summary

Dermatologic committee will discuss NDA 20-996 for Dermex Pharmaceuticals' zinc oxinate ointment for treatment of actinic keratosis, basal cell carcinoma and squamous cell carcinoma at its June 29 meeting. The committee will also discuss Schering-Plough's NDA for Lotrisone the same day (1"The Pink Sheet" May 29, In Brief). The meeting will be at the Holiday Inn in Bethesda, Md. at 10 a.m. The committee review of J&J's miconazole nitrate will be on June 30 at 8:30 a.m

You may also be interested in...

Schering-Plough Lotrisone

FDA Dermatologic & Ophthalmic Drugs Advisory Committee will meet June 29 to discuss NDA 20-010 for Lotrisone lotion (clotrimazole/betamethasone) for the treatment of tinea pedis, tinea cruris and tinea corporis

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts